valganciclovir

Overview

Valganciclovir is an antiviral prodrug (converted to ganciclovir) that inhibits EBV lytic replication. It is evaluated in EBV-associated nasopharyngeal carcinoma (NPC) in strategies that exploit EBV lytic reactivation to sensitize tumor cells.

Evidence in the corpus

• Valganciclovir listed as an EBV-targeting antiviral agent under investigation in the context of EBV-associated R/M NPC therapeutic strategies, exploiting EBV viral machinery for tumor-specific cytotoxicity PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.